JP2008538183A - Ｂ型インフルエンザ菌 - Google Patents

Ｂ型インフルエンザ菌 Download PDF

Info

Publication number
JP2008538183A
JP2008538183A JP2008504533A JP2008504533A JP2008538183A JP 2008538183 A JP2008538183 A JP 2008538183A JP 2008504533 A JP2008504533 A JP 2008504533A JP 2008504533 A JP2008504533 A JP 2008504533A JP 2008538183 A JP2008538183 A JP 2008538183A
Authority
JP
Japan
Prior art keywords
polypeptide
present
nucleic acid
sequence
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008504533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538183A5 (enExample
Inventor
ベガ マシグナニ，
リノ ラプオーリ，
エルベ テッテリン，
Original Assignee
ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド
ジ インスティチュート フォー ゲノミック リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド, ジ インスティチュート フォー ゲノミック リサーチ filed Critical ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド
Publication of JP2008538183A publication Critical patent/JP2008538183A/ja
Publication of JP2008538183A5 publication Critical patent/JP2008538183A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Materials For Photolithography (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2008504533A 2005-03-30 2006-03-30 Ｂ型インフルエンザ菌 Pending JP2008538183A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66792105P 2005-03-30 2005-03-30
PCT/US2006/012606 WO2006110413A2 (en) 2005-03-30 2006-03-30 Haemophilus influenzae type b

Publications (2)

Publication Number Publication Date
JP2008538183A true JP2008538183A (ja) 2008-10-16
JP2008538183A5 JP2008538183A5 (enExample) 2009-05-14

Family

ID=37087506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008504533A Pending JP2008538183A (ja) 2005-03-30 2006-03-30 Ｂ型インフルエンザ菌

Country Status (11)

Country Link
US (4) US20100034822A1 (enExample)
EP (1) EP1871888A4 (enExample)
JP (1) JP2008538183A (enExample)
CN (1) CN101687025A (enExample)
AU (1) AU2006235045A1 (enExample)
BR (1) BRPI0609460A2 (enExample)
CA (1) CA2602665A1 (enExample)
MX (1) MX2007012057A (enExample)
NZ (2) NZ562381A (enExample)
RU (1) RU2007139915A (enExample)
WO (1) WO2006110413A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
SG194886A1 (en) * 2011-05-11 2013-12-30 Riesbeck Healthcare Sweden Ab Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
AR090303A1 (es) * 2013-03-11 2014-11-05 Consejo Nac Invest Cient Tec Polipeptido mutado, cepa de bacterias que lo comprende y metodos para detectar diferentes cationes metalicos simultaneamente
JP2016521711A (ja) 2013-06-10 2016-07-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｍｖ中和抗原結合性タンパク質
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201508860D0 (en) 2015-05-22 2015-07-01 Nat Univ Ireland Diagnostic method
WO2018076008A1 (en) * 2016-10-21 2018-04-26 The Research Foundation For The State University Of New York Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3931206A1 (en) * 2019-02-27 2022-01-05 Evaxion Biotech ApS Vaccines targeting h. influenzae
GB2599573A (en) * 2019-05-31 2022-04-06 Rhogen Biotech Llc Compositions and methods for detoxifying bacterial endotoxins
US11357845B2 (en) * 2019-07-08 2022-06-14 The Trustees Of The University Of Pennsylvania Protein antigens for vaccinating against nontypeable Haemophilus influenzae
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
AU2021372524A1 (en) * 2020-10-30 2023-05-04 Gen-Probe Incorporated Compositions and methods for detecting influenza a, influenza b, and sars-cov-2
US20240350410A1 (en) 2021-08-16 2024-10-24 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
US20250134824A1 (en) 2021-08-16 2025-05-01 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
US20260124157A1 (en) 2024-08-09 2026-05-07 Genvax Technologies, Inc. Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004516805A (ja) * 2000-03-21 2004-06-10 エリトラ ファーマシューティカルズ，インコーポレイテッド 原核生物における必須遺伝子の同定
WO2004113371A2 (en) * 2003-06-26 2004-12-29 Chiron Srl Virulence-associated adhesins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355450B1 (en) * 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6593114B1 (en) * 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6914131B1 (en) * 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
US6730827B1 (en) * 1998-07-14 2004-05-04 E. I. Du Pont De Nemours And Company Genes encoding plant adenosine 5′-phosphosulfate reductase
US7365185B2 (en) * 2000-07-19 2008-04-29 Monsanto Technology Llc Genomic plant sequences and uses thereof
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
US7241867B2 (en) * 2003-03-06 2007-07-10 Children's Hospital, Inc. Polypeptide encoded by a nucleotide sequence of a nontypeable strain of Haemophilus influenzae genome
GB0410866D0 (en) * 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP2343312A1 (en) * 2005-06-16 2011-07-13 Nationwide Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable haemophilus influenzae

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004516805A (ja) * 2000-03-21 2004-06-10 エリトラ ファーマシューティカルズ，インコーポレイテッド 原核生物における必須遺伝子の同定
WO2004113371A2 (en) * 2003-06-26 2004-12-29 Chiron Srl Virulence-associated adhesins

Also Published As

Publication number Publication date
WO2006110413A2 (en) 2006-10-19
NZ591415A (en) 2012-10-26
US20160024157A1 (en) 2016-01-28
NZ562381A (en) 2011-06-30
CA2602665A1 (en) 2006-10-19
CN101687025A (zh) 2010-03-31
RU2007139915A (ru) 2009-05-10
US20140302078A1 (en) 2014-10-09
AU2006235045A1 (en) 2006-10-19
EP1871888A2 (en) 2008-01-02
WO2006110413A9 (en) 2010-01-14
BRPI0609460A2 (pt) 2010-04-13
US20120093868A1 (en) 2012-04-19
EP1871888A4 (en) 2013-08-21
US20100034822A1 (en) 2010-02-11
MX2007012057A (es) 2007-11-23

Similar Documents

Publication Publication Date Title
RU2450019C2 (ru) Полипептиды из neisseria meningitidis
JP2008506364A (ja) 型分類不能なＨａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ由来のポリペプチド
JP5960055B2 (ja) 改変髄膜炎菌ｆＨＢＰポリペプチド
BRPI0609460A2 (pt) haemophilus influenzae tipo b
US20090104218A1 (en) Group B Streptococcus
JP2017031221A (ja) 髄膜炎菌のｎｍｂ１８７０のキメラ、ハイブリッドおよびタンデムポリペプチド
JP6008741B2 (ja) 肺炎球菌ＲｒｇＢクレイドの組み合わせ
JP2007533729A (ja) タンパク質を使用する髄膜炎菌の血清群ｙに対する免疫
CN102770444A (zh) 免疫原性蛋白和组合物
JP2012532600A (ja) 保存された大腸菌免疫原
ES2478010T3 (es) Péptidos que imitan epítopos protectores sin reactividad cruzada en seres humanos del polisacárido capsular de meningococo del grupo B
JP6401148B2 (ja) 抗原および抗原の組み合わせ
CN101213205A (zh) B族链球菌
JP2025518168A (ja) 免疫原性組成物
Creasy Daugherty et al.(43) Pub. Date: Mar. 22, 2012
AU2012203509A1 (en) Polypeptides from Neisseria meningitides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120416